BioCentury
ARTICLE | Clinical News

Biogen discontinuing natalizumab for stroke after Phase IIb miss

February 9, 2018 4:23 PM UTC

Biogen Inc. (NASDAQ:BIIB) discontinued development of natalizumab to treat acute ischemic stroke after the drug missed the primary and secondary endpoints in the Phase IIb ACTION 2 trial in the indication.

Biogen markets natalizumab, a humanized mAb against integrin alpha(4) (VLA-4; CD49D), as Tysabri to treat patients with relapsing forms of multiple sclerosis and for moderately to severely active Crohn’s disease. The company said the ACTION 2 data do not impact the benefit-risk profile of the drug's approved indications...